Anti-Human RANTES (CCL5) (Monoclonal Mouse) 0 ComentariosSubmit a Review Detalles del Producto Nùmero de Catalogo 500-M75 Descripcion Source: Monoclonal Mouse Preparation: Produced in BALB/c mice immunized with highly pure Recombinant Human RANTES (CCL5). Anti-Human RANTES (CCL5)-specific antibody was purified from ascites fluid by Protein A affinity chromatography. Immunogen: E.coli derived Recombinant Human RANTES (CCL5) (PeproTech catalog# 300-06) Sandwich ELISA: In a sandwich ELISA (assuming 100μl/well), a concentration of 2.0-4.0 μg/ml of this antibody will detect at least 500pg/ml of Recombinant Human RANTES when used with PeproTech’s Biotinylated Antigen Affinity Purified anti-Human RANTES (CCL5) (500-P36BT) as the detection antibody at a concentration of approximately 0.5-1.0 μg/ml. Western Blot: To detect Human RANTES by Western Blot analysis this antibody can be used at a concentration of 0.5-1.0 μg/ml. When used in conjunction with compatible secondary reagents the detection limit for Recombinant Human RANTES is 0.25-2.0 ng/lane, under reducing conditions and 0.25-0.5 ng/lane, under non-reducing conditions. Note: Additional applications tested on a lot-to-lot basis. Please contact Technical Support for more information. crossreactivity: Human References SDS Búsqueda del CoA Product Line Country Of Origin: USA Not for human use. Research Interest AIDS/HIV Angiogenesis/Cardiovascular Chemotaxis Immune System Inflammation Neurobiology Wound Healing Allergy Transplantation product.subtitle.recentcitations Primer autor Soria, G Titulo Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. Citar BMC Cancer; 11 pg130 PudMed id 21486440 Primer autor Yaal-Hahoshen, N Titulo The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Citar Clinical cancer research : an official journal of the American Association for Cancer Research; 12(15) pg4474-80 PudMed id 16899591 Primer autor Azenshtein, E Titulo The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Citar Cancer Research; 62(4) pg1093-102 PudMed id 11861388